Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy - PubMed (original) (raw)
Controlled Clinical Trial
. 2012 Jun;153(6):1193-1198.
doi: 10.1016/j.pain.2012.02.021. Epub 2012 Apr 3.
Affiliations
- PMID: 22480803
- DOI: 10.1016/j.pain.2012.02.021
Controlled Clinical Trial
Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy
David Yarnitsky et al. Pain. 2012 Jun.
Abstract
This study aims to individualize the selection of drugs for neuropathic pain by examining the potential coupling of a given drug's mechanism of action with the patient's pain modulation pattern. The latter is assessed by the conditioned pain modulation (CPM) and temporal summation (TS) protocols. We hypothesized that patients with a malfunctioning pain modulation pattern, such as less efficient CPM, would benefit more from drugs augmenting descending inhibitory pain control than would patients with a normal modulation pattern of efficient CPM. Thirty patients with painful diabetic neuropathy received 1 week of placebo, 1 week of 30 mg/d duloxetine, and 4 weeks of 60 mg/d duloxetine. Pain modulation was assessed psychophysically, both before and at the end of treatment. Patient assessment of drug efficacy, assessed weekly, was the study's primary outcome. Baseline CPM was found to be correlated with duloxetine efficacy (r=0.628, P<.001, efficient CPM is marked negative), such that less efficient CPM predicted efficacious use of duloxetine. Regression analysis (R(2)=0.673; P=.012) showed that drug efficacy was predicted only by CPM (P=.001) and not by pretreatment pain levels, neuropathy severity, depression level, or patient assessment of improvement by placebo. Furthermore, beyond its predictive value, the treatment-induced improvement in CPM was correlated with drug efficacy (r=-0.411, P=.033). However, this improvement occurred only in patients with less efficient CPM (16.8±16.0 to -1.1±15.5, P<.050). No predictive role was found for TS. In conclusion, the coupling of CPM and duloxetine efficacy highlights the importance of pain pathophysiology in the clinical decision-making process. This evaluative approach promotes personalized pain therapy.
Trial registration: ClinicalTrials.gov NCT01363284.
Copyright © 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Similar articles
- A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. Wernicke JF, et al. Neurology. 2006 Oct 24;67(8):1411-20. doi: 10.1212/01.wnl.0000240225.04000.1a. Neurology. 2006. PMID: 17060567 Clinical Trial. - Duloxetine for treating painful neuropathy or chronic pain.
Lunn MP, Hughes RA, Wiffen PJ. Lunn MP, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007115. doi: 10.1002/14651858.CD007115.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821395 Updated. Review. - Duloxetine vs. placebo in patients with painful diabetic neuropathy.
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Goldstein DJ, et al. Pain. 2005 Jul;116(1-2):109-18. doi: 10.1016/j.pain.2005.03.029. Pain. 2005. PMID: 15927394 Clinical Trial. - A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. Raskin J, et al. Pain Med. 2005 Sep-Oct;6(5):346-56. doi: 10.1111/j.1526-4637.2005.00061.x. Pain Med. 2005. PMID: 16266355 Clinical Trial. - Review of duloxetine in the management of diabetic peripheral neuropathic pain.
Smith T, Nicholson RA. Smith T, et al. Vasc Health Risk Manag. 2007;3(6):833-44. Vasc Health Risk Manag. 2007. PMID: 18200804 Free PMC article. Review.
Cited by
- Test-retest and interrater reliability of experimental within-subject variability of pain reports as assessed by the focused analgesia selection test.
Agostinho M, Shani A, Canaipa R, Treister R. Agostinho M, et al. Pain Rep. 2024 Aug 16;9(5):e1175. doi: 10.1097/PR9.0000000000001175. eCollection 2024 Oct. Pain Rep. 2024. PMID: 39161417 Free PMC article. - Change in Endogenous Pain Modulation Depending on Emotional States in Healthy Subjects: A Randomized Controlled Trial.
Lang-Illievich K, Klivinyi C, Ranftl J, Elhelali A, Hammer S, Szilagyi IS, Bornemann-Cimenti H. Lang-Illievich K, et al. Pain Ther. 2024 Oct;13(5):1287-1298. doi: 10.1007/s40122-024-00642-1. Epub 2024 Aug 5. Pain Ther. 2024. PMID: 39102098 Free PMC article. - The interaction between psychological factors and conditioned pain modulation.
Petersen KK. Petersen KK. Br J Pain. 2024 Aug;18(4):312-313. doi: 10.1177/20494637241263306. Epub 2024 Jun 19. Br J Pain. 2024. PMID: 39092210 No abstract available. - Effectiveness of Duloxetine versus Other Therapeutic Modalities in Patients with Diabetic Neuropathic Pain: A Systematic Review and Meta-Analysis.
Valenzuela-Fuenzalida JJ, López-Chaparro M, Barahona-Vásquez M, Campos-Valdes J, Cordero Gonzalez J, Nova-Baeza P, Orellana-Donoso M, Suazo-Santibañez A, Oyanedel-Amaro G, Gutiérrez Espinoza H. Valenzuela-Fuenzalida JJ, et al. Pharmaceuticals (Basel). 2024 Jun 28;17(7):856. doi: 10.3390/ph17070856. Pharmaceuticals (Basel). 2024. PMID: 39065707 Free PMC article. Review. - Cross-sectional and longitudinal analysis of conditioned pain modulation and pain in fibromyalgia: CPM as an effect modifier of pain changes over time.
Castelo-Branco L, Pacheco-Barrios K, Cardenas-Rojas A, de Melo PS, Gianlorenco AC, Gonzalez-Mego P, Marduy A, Shaik ES, Teixeira P, Caumo W, Fregni F. Castelo-Branco L, et al. Physiother Res Int. 2024 Apr;29(2):e2072. doi: 10.1002/pri.2072. Epub 2024 Feb 6. Physiother Res Int. 2024. PMID: 39055778
References
- Arendt-Nielsen L, Frøkjaer JB, Staahl C, Graven-Nielsen T, Huggins JP, Smart TS, Drewes AM. Effects of gabapentin on experimental somatic pain and temporal summation. Reg Anesth Pain Med. 2007;32:382-388.
- Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-1123.
- Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment [review]. Lancet Neurol. 2010;9:807-819.
- Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med. 1972;52:81-85.
- Chang L. Brain responses to visceral and somatic stimuli in irritable bowel syndrome: a central nervous system disorder? Gastroenterol Clin North Am. 2005;34:271-279.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical